Joachim Pohlenz1, Wiebke Ahrens, Olaf Hiort. 1. Children's Hospital, Johannes Gutenberg-University, Langenbeckstrasse 1, D-55101 Mainz, Germany. pohlenz@mail.uni-mainz.de
Abstract
OBJECTIVE: To identify the molecular defect by which psychomotor retardation is caused in two brothers with congenital hypothyroidism who received adequate treatment with l-thyroxine. CASE REPORT: A six-year-old boy presented with psychomotor retardation and congenital primary hypothyroidism (CH). The patient had a normal blood thyrotrophin (TSH) level on neonatal screening, but low total serum thyroxine and triiodothyronine concentrations prompting thyroid hormone substitution shortly after birth. Nevertheless, psychomotor development was retarded and the patient underwent further investigation. Typical features of Albright's hereditary osteodystrophy (AHO) such as round face, obesity, and shortened 1st, 4th and 5th metacarpals were found. METHODS AND RESULTS: Further investigation confirmed AHO with pseudohypoparathyroidism (PHP) type Ia. The boy had a mild resistance to parathyroid hormone and a reduced adenylyl cyclase stimulating protein (Gsalpha) activity in erythrocytes. DNA analysis detected a new heterozygous mutation (L338N) in the Gsalpha protein (GNAS1) gene. This mutation was also present in the patient's brother who had similar features and was also treated with thyroid hormone because of CH, and in the phenotypically normal-looking mother who had a normal calcium metabolism but a reduced Gsalpha protein activity in erythrocytes suggestive of pseudopseudohypoparathyroidism. CONCLUSION: In patients with CH, in whom the neurological outcome is poor even under adequate thyroid hormone substitution, PHP Ia may be suspected, especially when symptoms of AHO are present.
OBJECTIVE: To identify the molecular defect by which psychomotor retardation is caused in two brothers with congenital hypothyroidism who received adequate treatment with l-thyroxine. CASE REPORT: A six-year-old boy presented with psychomotor retardation and congenital primary hypothyroidism (CH). The patient had a normal blood thyrotrophin (TSH) level on neonatal screening, but low total serum thyroxine and triiodothyronine concentrations prompting thyroid hormone substitution shortly after birth. Nevertheless, psychomotor development was retarded and the patient underwent further investigation. Typical features of Albright's hereditary osteodystrophy (AHO) such as round face, obesity, and shortened 1st, 4th and 5th metacarpals were found. METHODS AND RESULTS: Further investigation confirmed AHO with pseudohypoparathyroidism (PHP) type Ia. The boy had a mild resistance to parathyroid hormone and a reduced adenylyl cyclase stimulating protein (Gsalpha) activity in erythrocytes. DNA analysis detected a new heterozygous mutation (L338N) in the Gsalpha protein (GNAS1) gene. This mutation was also present in the patient's brother who had similar features and was also treated with thyroid hormone because of CH, and in the phenotypically normal-looking mother who had a normal calcium metabolism but a reduced Gsalpha protein activity in erythrocytes suggestive of pseudopseudohypoparathyroidism. CONCLUSION: In patients with CH, in whom the neurological outcome is poor even under adequate thyroid hormone substitution, PHP Ia may be suspected, especially when symptoms of AHO are present.
Authors: R Fölster-Holst; F G Riepe; W Ahrens; M Möller; J Brasch; C-J Partsch; O Hiort; W G Sippell Journal: Hautarzt Date: 2006-10 Impact factor: 0.751
Authors: Fiorella A Solari; Oliver Pagel; Frauke Swieringa; Florian Beck; Jingnan Huang; Marion A H Feijge; Kerstin Jurk; Irene M L W Körver-Keularts; Nadine J A Mattheij; Jörg Faber; Joachim Pohlenz; Alexandra Russo; Connie T R M Stumpel; Dirk E Schrander; Barbara Zieger; Paola E J van der Meijden; René P Zahedi; Albert Sickmann; Johan W M Heemskerk Journal: Sci Rep Date: 2020-07-09 Impact factor: 4.379
Authors: Michael T Cheeseman; Kate Vowell; Tertius A Hough; Lynn Jones; Paras Pathak; Hayley E Tyrer; Michelle Kelly; Roger Cox; Madhuri V Warren; Jo Peters Journal: PLoS One Date: 2012-12-19 Impact factor: 3.240